BAIT
DOT1L
DOT1, KMT4
DOT1-like histone H3K79 methyltransferase
GO Process (3)
GO Function (3)
GO Component (0)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Homo sapiens
PREY
PABPC1
PAB1, PABP, PABP1, PABPC2, PABPL1
poly(A) binding protein, cytoplasmic 1
GO Process (17)
GO Function (6)
GO Component (10)
Gene Ontology Biological Process
- RNA metabolic process [TAS]
- cellular protein metabolic process [TAS]
- gene expression [TAS]
- gene silencing by RNA [ISS]
- mRNA metabolic process [TAS]
- mRNA polyadenylation [TAS]
- mRNA splicing, via spliceosome [IC]
- mRNA stabilization [TAS]
- negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay [IDA]
- nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [TAS]
- nuclear-transcribed mRNA catabolic process, nonsense-mediated decay [TAS]
- nuclear-transcribed mRNA poly(A) tail shortening [TAS]
- positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [ISS]
- positive regulation of nuclear-transcribed mRNA poly(A) tail shortening [ISS]
- positive regulation of translation [TAS]
- translation [TAS]
- translational initiation [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Affinity Capture-MS
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.
Publication
Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor alpha (ER?) signaling to the genome. Targeting components of the ER? pathway in these tumors represents, therefore, a rational way ... [more]
Breast Cancer Res Dec. 18, 2021; 24(1);52 [Pubmed: 35850772]
Throughput
- Low Throughput
Curated By
- BioGRID